FDA May Authorize Pfizer-BioNTech's COVID-19 Booster For 5-11 Year Kids Soon: NYT - Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX)

The FDA is expected to authorize a booster shot of Pfizer Inc PFE / BioNTech SE's BNTX COVID-19 vaccine for children aged 5 to 11 probably by today, the New York Times reported, citing people familiar with the matter.
The companies submitted an application to the FDA for authorization last month.
They have cited data from a mid-to-late-stage study showing the third dose of their shot increased protection against the original coronavirus version and the omicron variant among children aged 5-11 years.
Other research has suggested that the protection against infection provided by two Pfizer shots wanes within just a few weeks for 5 to 11-year-olds, thus all the more reason for a booster dose.
Related: FDA Sets Review Dates For Pfizer, Moderna COVID-19 Shot For Kids, Plus Novavax EUA.
It is unclear how much demand there is for the third dose in the age group. According to data from the U.S. Centers for Disease Control and Prevention, just 28.8% of children aged 5 to 11 are fully vaccinated.
Price Action: PFE shares closed at $50.60, and BNTX stock closed at $151.73 on Monday.
Photo by x3 from Pixabay